CVS Health stock weighs higher outlook against medical cost risks
Published on 11/12/2026 at 15:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points for investors
- CVS Health lifted its full-year adjusted earnings and operating cash-flow outlook after stronger third-quarter results.
- Health Care Benefits improved as the medical benefit ratio declined year over year.
- Aetna enters 2027 with more than 69 percent of Medicare Advantage members in plans rated at least four stars.
CVS Health raised its full-year 2026 outlook on November 4 after reporting stronger third-quarter results. The company also highlighted Aetna's positioning for 2027, with more than 69 percent of its Medicare Advantage members enrolled in plans rated at least four stars by the Centers for Medicare & Medicaid Services. The figures and guidance were published in the CVS Health investor release.
Higher guidance, uneven operating picture
Third-quarter revenue rose 5.4 percent year over year to USD 108.4 billion. Adjusted earnings per share increased to USD 2.09 from USD 1.60, while adjusted operating income reached USD 4.194 billion, up 21.2 percent.
CVS Health now expects full-year adjusted earnings per share of at least USD 8.20, compared with a previous range of USD 7.90 to USD 8.10. Operating cash-flow guidance rose to at least USD 15.5 billion from at least USD 11.5 billion. Management retained a cautious stance because medical cost trends remain elevated and macroeconomic headwinds could affect the remainder of the year.
Insurance recovery remains central
The Health Care Benefits segment produced adjusted operating income of USD 912 million, compared with USD 314 million a year earlier. Its medical benefit ratio improved to 91.3 percent from 92.8 percent, mainly because of better performance in the Government business. CVS Health also said prior-year health care cost estimates developed favorably by USD 1.3 billion during the first nine months.
The comparison with the prior year needs context. Third-quarter GAAP diluted earnings per share were USD 1.68, versus a loss of USD 3.13, partly because the prior-year period included a USD 5.7 billion goodwill impairment charge. Adjusted results exclude specified items and therefore present a different view of underlying performance.
Current trading and investor focus
CVS Health stock traded at 80.54 euros on Lang & Schwarz at 3:40 p.m. CET on Thursday, November 12, 2026.
CVS Health Corp.
- ISIN: US1266501006
- Ticker: CVS
- Latest quote: 80.54 euros on Lang & Schwarz, November 12, 2026, 3:40 p.m. CET
- Third-quarter revenue: USD 108.4 billion
- Full-year adjusted EPS outlook: At least USD 8.20
For investors, the raised outlook supports the recovery case in insurance and pharmacy operations, but the cost trend warning remains a counterweight. The next focus is whether improved medical performance can persist while CVS Health manages pharmacy reimbursement pressure and the execution demands of its broader strategy.
The broader U.S. market remains the relevant reference frame for this U.S.-listed healthcare company: Current S&P 500 coverage.
